

CRR
JOURNAL
OF CARDIORESPIRATORY RESEARCH

ISSN 2181-0974
DOI 10.26739/2181-0974



Journal of
CARDIORESPIRATORY
RESEARCH

Special Issue 1.1

2023



ИННОВАЦИОННЫЕ ТЕХНОЛОГИИ В ЗДРАВООХРАНЕНИИ: НОВЫЕ ВОЗМОЖНОСТИ ДЛЯ ВНУТРЕННЕЙ МЕДИЦИНЫ

МАТЕРИАЛЫ

II международной научно-практической
конференции (Самарканд, 7-8 апрель 2023 г.)

Под редакцией
Ж.А. РИЗАЕВА

ТОМ II

Самарканд-2023

МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ
РЕСПУБЛИКИ УЗБЕКИСТАН

ЖУРНАЛ
КАРДИОРЕСПИРАТОРНЫХ
ИССЛЕДОВАНИЙ

Главный редактор: Э.Н.ТАШКЕНБАЕВА

Учредитель:

Самаркандский государственный
медицинский университет

Tadqiqot.uz

Ежеквартальный
научно-практический
журнал

ISSN: 2181-0974

DOI: 10.26739/2181-0974

N°SI-1.1
2023

ПРОЯВЛЕНИЕ СИНДРОМА ДИСПЛАЗИИ СОЕДИНИТЕЛЬНОЙ ТКАНИ ЧЕЛЮСТНО-ЛИЦЕВОЙ ОБЛАСТИ У ДЕТЕЙ Г. ИЖЕВСКА	
Сосулина Л.Л., Мосеева М.В., Тимофеева Е.С., Фаррахова Р.И.	188
ТЕЧЕНИЕ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ, В ЗАВИСИМОСТИ ОТ ВОЗРАСТА, ПОЛОВЫХ ОСОБЕННОСТЕЙ И НАСЛЕДСТВЕННОГО ПРЕМОРБИДА	
Хамраева Н.А.	189
ГЕРИАТРИЧЕСКИЕ ОСОБЕННОСТИ РЕВМАТОИДНОГО АРТРИТА	
Яхшиев Б. Т., Исламова К.А.	191
EVALUATION OF IMMUNO-INFLAMMATORY RELATIONSHIPS IN PATIENTS WITH CHRONIC HEART FAILURE AND RHEUMATOID ARTHRITIS	
Eshmamatova F.B., Khusainova M.A.	192
FEATURES OF THE CLINIC COURSE OF RHEUMATOID ARTHRITIS IN PATIENTS WITH THYROID PATHOLOGY	
Fayziyev X.F., Shonazarova N.X.	193
THE EFFECTIVENESS OF BISOPROLOL IN PATIENTS WITH RHEUMATIC HEART DISEASE WITH CHRONIC HEART FAILURE	
Makhmudova M.S., Shukurdjanova S.M., Nuritdinova N.B.	194
ACUTE RHEUMATIC FEVER IN CHILDREN	
Umarova S. S., Mukhamadieva L.A.	195
REVMATOID ARTRIT BILAN KASALLANGAN BEMORLARDA MUSHAKLARNI RAG‘BATLANTIRISH MAQSADIDA ELEKTROMIOSTIMULYATSIYA MUOLAJALARINI QO‘LLASHNING AHAMIYATI	
Axmedov I.A., Amrillaev U.Sh.	196
REVMATIK KASALLIKLAR BILAN OG‘RIGAN BEMOR BOLALARDA ANEMIK SINDROMNI RIVOJLANISHIGA OLIB KELUVCHI OMILLAR	
Elomonova J.Y., Uralov R.Sh.	198
ULTRATOVUSH TEKSHIRUV ERTA RIVOJLANGAN OSTEOARTROZ KASALLIGIDAGI DIAGNOSTIK AHAMIYATI	
Fazliddinov J. Z., Islamova K.A.	199
METOBOLIK SINDROM BILAN BIRGALIKDA UCHRAGAN PODAGRANING O‘ZIGA XOS XUSUSIYATLARI	
G‘afurova M, Meliyev Sh	200
FIZIOTERAPIYA MUOLAJALARINING ERTA RIVOJLANGAN OSTEOARTROZ KASALLIGINI KOMPLEKS DAVOLASHDAGI O‘RNI	
Islamova K.A.1, Hamraeva N.A.2	201
REVMATOID ARTRIT KASALLIGIDA KOMORBID XOLATLAR	
Tairova Z.K., Shodikulova G.Z.	202



THE EFFECTIVENESS OF BISOPROLOL IN PATIENTS WITH RHEUMATIC HEART DISEASE WITH CHRONIC HEART FAILURE

Makhmudova M.S., Shukurdjanova S.M., Nuritdinova N.B.

Tashkent Medical Academy

Tashkent, Uzbekistan

Introduction. Neurohormonal factors (an increase in the activity of the sympathetic-adrenal and renin-angiotensin systems, an increase in the production of aldosterone) and cytokines are involved in the pathogenesis of heart failure, causing various vasoconstrictor effects, which initially have a compensatory value, but then lead to the hemodynamic overload of the heart. The effect on these mechanisms (neurohormonal and immunological unloading) is possible with the appointment of beta-blockers, ACE inhibitors, as well as veroshpiron.

Purpose. To study the effect of bisoprolol on immunological parameters and quality of life in patients with rheumatic heart defects complicated by CHF.

Materials and methods: The study included 96 patients with mitral and aortic heart defects with a predominance of rheumatic etiology stenosis, complicated by CHF of functional classes II-III (FC) at the age of 18-64 years. The patients were randomized into two groups. The first group included 48 patients who received bisoprolol in addition to standard therapy. Immunological parameters of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (proinflammatory cytokines) were determined by solid-phase enzyme immunoassay according to the standard method. The quality of life was assessed according to the Minnesota questionnaire "Life with heart failure.

Results. After 3 months of treatment, the first group showed a decrease in proinflammatory cytokines TNF-alpha by 22.6%, interleukin-6 by 25.3%. In the second group, TNF-alpha decreased by 15.8%, interleukin-6 decreased by 18.1%. There were improvements in the clinical condition and quality of life, an increase in exercise tolerance. Bisoprolol is an effective drug for the treatment of rheumatic heart defects complicated by CHF II-III FC, having a beneficial effect on immunological parameters (reducing the amount of pro-inflammatory cytokines) and improving the quality of life.